{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:07:07Z","timestamp":1791378427811,"version":"4.3.2"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172504"],"award-info":[{"award-number":["81172504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background.<\/jats:title><jats:p>Left ventricular ejection fraction (LVEF) is used routinely to monitor cardiac dysfunction associated with breast cancer treatment. In this study the prevalence of early left ventricular diastolic dysfunction (LVDD) and its relationship to the dose-volume of the heart irradiated were evaluated in HER2-positive breast cancer patients undergoing concurrent trastuzumab and adjuvant radiotherapy (RT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods.<\/jats:title><jats:p>Data from 40 breast cancer patients treated with concurrent trastuzumab and left-sided adjuvant RT between September 2011 and October 2012 were collected prospectively. For comparison, 32 patients treated with concurrent trastuzumab and right-sided adjuvant RT and 71 patients treated with left-sided RT alone were collected retrospectively. Echocardiography was obtained before RT, immediately following RT, and 3 and 6 months after RT. Doses to the heart and left ventricle (LV) were quantified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Prior to RT with concurrent trastuzumab, 11 of 29 (left) and 8 of 25 (right) patients with normal baseline left ventricular diastolic function (LVDF) developed LVDD. In patients receiving left-sided RT alone, 12 of 61 patients with normal baseline LVDF developed LVDD. Dmean, D15\u2013D40, D60\u2013D70, and V3\u2013V10 of the LV were significantly higher in patients who developed LVDD after concurrent trastuzumab and left-sided RT. In contrast, only two patients developed grade 1 LVEF decrease after both concurrent treatment and left-sided RT alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Changes in LVDF compared with LVEF are more sensitive for early detection of cardiotoxicity. The dose-volume of the heart contributes significantly to the risk of LVDD in patients with left-sided breast cancer treated concurrently with trastuzumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice:<\/jats:title><jats:p>Abnormalities in diastolic function are more sensitive than changes in the left ventricular ejection fraction for detecting acute cardiotoxicity and are related to the dose-volume of the heart irradiated in patients with left-sided breast cancer receiving radiotherapy concurrently with trastuzumab. This result highlights the importance of decreasing the dose-volume of heart irradiated as a protective strategy in the treatment setting of concurrent trastuzumab and radiotherapy. Diastolic dysfunction may serve as a more sensitive tool for the early detection of cardiac damage and should be incorporated as a routine parameter in the functional monitoring of cardiotoxicity.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0299","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T01:12:33Z","timestamp":1430529153000},"page":"605-614","source":"Crossref","is-referenced-by-count":42,"title":["Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab"],"prefix":"10.1093","volume":"20","author":[{"given":"Lu","family":"Cao","sequence":"first","affiliation":[{"name":"Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cai","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Chang","sequence":"additional","affiliation":[{"name":"Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China;"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Yu","family":"Miao","sequence":"additional","affiliation":[{"name":"Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China;"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Yu","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Zhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Li","family":"Ma","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[{"name":"Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China;"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Mao","family":"Guo","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China;"},{"name":"Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,5,1]]},"reference":[{"key":"2021122309233058500_B1","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"key":"2021122309233058500_B2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","article-title":"Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries","volume":"6","author":"Darby","year":"2005","journal-title":"Lancet Oncol"},{"key":"2021122309233058500_B3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijrobp.2005.01.029","article-title":"The incidence and functional consequences of RT-associated cardiac perfusion defects","volume":"63","author":"Marks","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/dji067","article-title":"Risk of cardiac death after adjuvant radiotherapy for breast cancer","volume":"97","author":"Giordano","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2021122309233058500_B5","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1200\/JCO.2005.13.755","article-title":"Cardiac morbidity of adjuvant radiotherapy for breast cancer","volume":"23","author":"Patt","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309233058500_B6","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122309233058500_B7","doi-asserted-by":"crossref","first-page":"e21030","DOI":"10.1371\/journal.pone.0021030","article-title":"Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials","volume":"6","author":"Yin","year":"2011","journal-title":"PLoS One"},{"key":"2021122309233058500_B8","first-page":"1347","article-title":"Monoclonal antibody to HER-2\/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene","volume":"59","author":"Pietras","year":"1999","journal-title":"Cancer Res"},{"key":"2021122309233058500_B9","first-page":"1113","article-title":"Sensitization of breast cancer cells to radiation by trastuzumab","volume":"2","author":"Liang","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"2021122309233058500_B10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1179\/102453312X13376952196412","article-title":"Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children","volume":"17","author":"Sherief","year":"2012","journal-title":"Hematology"},{"key":"2021122309233058500_B11","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(13)60858-X","article-title":"Predictors of abnormal longitudinal strain using left ventricular speckle tracking in ambulatory hypertensive patients with preserved ejection fraction","volume-title":"J Am Coll Cardiol","author":"Mukherjee","year":"2013"},{"key":"2021122309233058500_B12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"2021122309233058500_B13","doi-asserted-by":"crossref","first-page":"E1442","DOI":"10.1016\/S0735-1097(13)61442-4","article-title":"Microvascular coronary dysfunction, left ventricular volumes and mass: Results from the women's ischemia syndrome evaluation-coronary vascular dysfunction study","volume":"61","author":"Zaya","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"(suppl)","key":"2021122309233058500_B14","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canrad.2014.01.001","article-title":"Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy","volume":"18","author":"Cao","year":"2014","journal-title":"Cancer Radiother"},{"key":"2021122309233058500_B16","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2021122309233058500_B17","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0360-3016(00)01396-1","article-title":"Intensity modulation to improve dose uniformity with tangential breast radiotherapy: Initial clinical experience","volume":"48","author":"Kestin","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B18","first-page":"411","article-title":"A simplified intensity modulated radiation therapy technique for difficult clinical cancer condition","volume":"15","author":"Hui","year":"2006","journal-title":"Chinese Journal of Radiation Oncology"},{"key":"2021122309233058500_B19","volume-title":"Radiation Therapy Oncology Group. Breast cancer contouring atlas"},{"key":"2021122309233058500_B20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B21","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ijrobp.2007.05.034","article-title":"Cardiac exposures in breast cancer radiotherapy: 1950s\u20131990s","volume":"69","author":"Taylor","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B22","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.09.022","article-title":"Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy","volume":"85","author":"Erven","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0894-7317(89)80026-4","article-title":"Descent of the base of the left ventricle: An echocardiographic index of left ventricular function","volume":"2","author":"Simonson","year":"1989","journal-title":"J Am Soc Echocardiogr"},{"key":"2021122309233058500_B24","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur Heart J"},{"key":"2021122309233058500_B25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ahj.2004.12.026","article-title":"Diastolic dysfunction after mediastinal irradiation","volume":"150","author":"Heidenreich","year":"2005","journal-title":"Am Heart J"},{"key":"2021122309233058500_B26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0360-3016(00)01531-5","article-title":"Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: Preliminary results","volume":"49","author":"Hardenbergh","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1040-8428(01)00227-X","article-title":"Radiation-associated cardiovascular disease","volume":"45","author":"Adams","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122309233058500_B28","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/annonc\/mdq590","article-title":"Concomitant trastuzumab with thoracic radiotherapy: A morphological and functional study","volume":"22","author":"Yavas","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122309233058500_B29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10549-011-1714-9","article-title":"Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer","volume":"130","author":"Cochet","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2021122309233058500_B30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"2021122309233058500_B31","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG Phase III Trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309233058500_B32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.radonc.2008.09.003","article-title":"Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single-institution study","volume":"90","author":"Shaffer","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122309233058500_B33","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/annonc\/mdn029","article-title":"Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: Acute toxicity analyses from the French multicentric study","volume":"19","author":"Belkac\u00e9mi","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122309233058500_B34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0735-1097(97)00144-7","article-title":"Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone","volume":"30","author":"Nishimura","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2021122309233058500_B35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0033-8389(22)01790-0","article-title":"Radiation-induced heart disease. Clinical and experimental aspects","volume":"9","author":"Stewart","year":"1971","journal-title":"Radiol Clin North Am"},{"key":"2021122309233058500_B36","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2007.06.060","article-title":"Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer?","volume":"69","author":"Beckham","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2009.07.1705","article-title":"Tomotherapy and multifield intensity-modulated radiotherapy planning reduce cardiac doses in left-sided breast cancer patients with unfavorable cardiac anatomy","volume":"78","author":"Coon","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309233058500_B38","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/annonc\/mds127","article-title":"Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: A multicenter cohort analysis","volume":"23","author":"Tarantini","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122309233058500_B39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1540-8175.1993.tb00032.x","article-title":"Pitfalls in the echo-Doppler assessment of diastolic dysfunction","volume":"10","author":"Grodecki","year":"1993","journal-title":"Echocardiography"},{"key":"2021122309233058500_B40","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1161\/01.CIR.0000015076.37047.D9","article-title":"Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: The Strong Heart Study","volume":"105","author":"Bella","year":"2002","journal-title":"Circulation"},{"key":"2021122309233058500_B41","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehi406","article-title":"The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: Correlation with echocardiographic and invasive measurements","volume":"26","author":"Tsch\u00f6pe","year":"2005","journal-title":"Eur Heart J"},{"key":"2021122309233058500_B42","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/annonc\/mdi152","article-title":"cTnT can be a useful marker for early detection of anthracycline cardiotoxicity","volume":"16","author":"Kilickap","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122309233058500_B43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ejechocard\/jep007","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"10","author":"Nagueh","year":"2009","journal-title":"Eur J Echocardiogr"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0299","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/6\/605\/41870639\/oncolo_20_6_605.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/6\/605\/41870639\/oncolo_20_6_605.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:39:35Z","timestamp":1691627975000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/6\/605\/6399687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,5,1]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0299","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,6,1]]},"published":{"date-parts":[[2015,5,1]]}}}